Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: moderate revenue growth, strong performance in specific segments, and effective tariff mitigation strategies, but also challenges like headwinds in China and lack of share buybacks. The Q&A reveals optimism about future growth and margin improvements, but some concerns remain unaddressed. The absence of a share buyback program and the challenges in emerging markets balance the positives, leading to a neutral stock price prediction over the next two weeks.
Key Financial Performance
Revenue $1.4 billion, with a 3.1% underlying growth and 1.6% reported after a 150 basis points headwind from foreign exchange. The growth includes the effect of 1 fewer trading day than in Q1 2024, which proportionately reduced growth by around 1.7 percentage points.
U.S. Revenue Growth 3.6% growth in the U.S. market, with a 5% growth in other established markets. The decline in emerging markets was 1.7%, primarily due to headwinds in China.
Orthopaedics Growth 3.2% growth in Orthopaedics, with 5.1% growth excluding China. The growth reflects a change in reporting practices around robotics.
Trauma & Extremities Growth 6.3% growth, driven by the EVOS Plating System and the AETOS Shoulder.
Advanced Wound Management Growth 3.8% growth, with Advanced Wound Care growing 2.5% and Advanced Wound Devices growing 15.7%, mainly driven by Negative Pressure Wound Therapy.
Tariff Impact Expected net impact of around $15 million to $20 million from recently announced tariffs, which the company expects to absorb within existing margin guidance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: ALLEVYN Ag+ SURGICAL is in the early stages of its U.S. launch, adding a new antimicrobial dressing to our foams portfolio.
Product Portfolio Expansion: Further developed cementless knee offering with the addition of LEGION Medial Stablized Inserts, which received 510(k) clearance.
Clinical Evidence: REGENETEN showed a highly statistically significant reduction in the re-tear rate with a 65% lower relative risk compared to repair alone.
Market Growth: Achieved 3.1% underlying revenue growth in Q1 2025, with 3.6% growth in the U.S. and 5% in other established markets.
Emerging Markets Performance: 1.7% decline in emerging markets due to headwinds in China, which are believed to have peaked.
Operational Improvements: Building on the operational and commercial improvements of the 12-Point Plan, leading to better product availability and commercial execution.
Cost Savings Impact: Expect to absorb the impact of recently announced tariffs within existing margin guidance, with a net impact of around $15 million to $20 million.
Strategic Focus: Continued focus on innovation-driven growth across key platforms, including Orthopaedics and Advanced Wound Management.
Market Positioning: Maintaining full year guidance on revenue growth and trading margin despite external challenges.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
China Market Headwinds: The company faced a 240 basis points headwind in China, which has now peaked, but it contributed to a 1.7% decline in emerging markets.
Tariffs Impact: The recently announced tariffs are expected to have a net impact of around $15 million to $20 million, which the company anticipates absorbing within its existing margin guidance.
Foreign Exchange Headwinds: The reported revenue growth was affected by a 150 basis points headwind from foreign exchange.
Supply Chain Challenges: The company is working to mitigate tariffs on products and raw materials imported into the U.S. and is leveraging its global manufacturing network to address supply chain issues.
Trading Day Effect: The company experienced a reduction in growth due to having one fewer trading day compared to the previous year, which is estimated to have reduced growth by around 1.7 percentage points.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
12-Point Plan: Operational and commercial improvements have been made, leading to better product availability and commercial execution.
Innovation-Driven Growth: Key platforms such as CORI, EVOS, REGENETEN, and Negative Pressure Wound Therapy are driving strong double-digit growth.
New Product Launches: Expanding offerings in high-growth categories including foams dressings and cementless knees.
Clinical Evidence: New data supporting OXINIUM and rotator cuff repair to enhance product adoption.
Revenue Growth Guidance: Full year guidance remains unchanged with expectations for higher growth in the remaining 9 months.
Impact of Tariffs: Expected net impact of tariffs is around $15 million to $20 million, which will be absorbed within existing margin guidance.
Q1 Revenue: Revenue for Q1 was $1.4 billion with a 3.1% underlying growth.
Trading Margin: Trading margin guidance remains unchanged for the full year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On your full year call, you shared some reasonably detailed thoughts on how to think about phasing. Has anything changed in your view as you move through Q1? Can you maybe remind us of how you see top line growth progressing in Q2 and beyond?
A:Q1 was our lowest growth quarter as guided. We expect growth to pick up sequentially in each quarter, with Sports growth ex-China near double digits and Orthopaedics improving to market growth levels by Q4.
Q:Could you maybe give us a little bit more color on what is driving growth within the REGENETEN product family? How big is it in your portfolio today?
A:REGENETEN utilization was primarily in the shoulder last year, but now 10% is in foot and ankle. It's a platform technology expected to be a meaningful growth driver.
Q:Could you shed more light on what's going on outside of the U.S. in the recon business?
A:We saw 2.7% growth for the quarter outside the U.S., with good growth in other recon categories.
Q:Could you just remind us of what your expectations would be at this stage for the FX impact on your margin this year?
A:We expect Forex to be broadly neutral, with a tailwind of 20-25 bps for the full year.
Q:Are you seeing a step-up in Q2?
A:We expect to see a step-up in Q2 and further in Q3.
Q:Could you talk a little bit more about the offsets you're implementing regarding tariffs?
A:We're focused on mitigating actions, including a flexible manufacturing network to minimize tariff impacts.
Q:Could you just give us a little bit more guidance on the margin progression around the Malaysia ramp-up?
A:The step-up in margin will come from the benefits of network actions and closing four plants, with production transferred to Memphis and Malaysia.
Q:Between the U.S. and Europe, how well positioned are you to mitigate tariff impacts?
A:Most volumes for Sports Medicine come from Costa Rica, which mitigates impacts from U.S. and Europe tariffs.
Q:Given the $15 million to $20 million impact from tariffs, is the lower end now more realistic?
A:No change in the guide; we expect to remain in the 19% to 20% margin range.
Q:Can you talk about the strength in CORI placement in the quarter and what is driving this regionally?
A:We're pleased with CORI placements, especially in hospital settings, and utilization rates remain healthy.
Q:Could you just remind us where China peaked as a percentage of sales and where you've come down to?
A:China peaked at about 7% of sales and is now down to about 1.9% for Q1.
Q:Does it still make commercial sense to maintain a presence in China?
A:Yes, we are profitable in China with our current book of business.
Q:Is there any more mitigation that you can do regarding tariffs for 2026?
A:We are confident in our ability to see increasing margins in 2026 and beyond.
Q:What is driving the strength in devices, and how sustainable do you feel that is?
A:Both single-use and traditional products are growing, and we expect continued performance.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific competitive dynamics in the hips market and the exact impact of tariffs on margins, using vague language about ongoing assessments and scenarios without providing concrete data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AET implementation
ALLEVYN SURGICAL
ARIS Wand
AWB
Advanced Wound
Arthroscopic Enabling
CATALYSTEM
China headwind
Deepak Nath
Enabling Technologies
FASTSEAL
Negative Pressure
Orthopaedics
Pressure Wound
Sports Medicine
Wound Therapy
cuff repair
decline
dressing foam
finish
foam dressing
headline
mix
peak China
product launch
rate
repair China
repair effect
result
rotator cuff
statement
tariff
technology
SNN Transcript
Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call highlighted strong financial performance with a 21% EPS increase and a $500 million share buyback. Trading margins expanded, and ROIC improved. Product updates like the CORI Shoulder platform and REGENETEN's market potential were promising. Despite some uncertainties in China and the skin substitutes market, the company maintains a positive outlook for 2026 with growth in key areas. The Q&A reflected confidence in strategic initiatives and competitive positioning, supporting a positive sentiment.
Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary presents a mixed outlook: strong product innovation and market strategy are offset by uncertainties in tariffs and CMS proposals. The Q&A session reveals management's cautious optimism, but with some unclear responses. Financial performance and guidance remain stable, yet the lack of clear answers on certain risks tempers enthusiasm. Given these factors, a neutral rating is appropriate as the stock may not significantly change over the next two weeks.
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Unknown5-2
The earnings call presents a mixed picture: moderate revenue growth, strong performance in specific segments, and effective tariff mitigation strategies, but also challenges like headwinds in China and lack of share buybacks. The Q&A reveals optimism about future growth and margin improvements, but some concerns remain unaddressed. The absence of a share buyback program and the challenges in emerging markets balance the positives, leading to a neutral stock price prediction over the next two weeks.
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture. Financial performance shows growth in revenue and trading profit, but gross margins have declined slightly. The unchanged dividend and improved free cash flow are positive, while headcount reductions and cost savings indicate efficiency efforts. However, management's unclear responses in the Q&A, particularly regarding inventory reduction and competitive dynamics in China, suggest some uncertainty. The overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
SNN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
